Log in

Neurotrope Stock Forecast, Price & News

-0.01 (-0.90 %)
(As of 09/25/2020 12:00 AM ET)
Today's Range
Now: $1.10
50-Day Range
MA: $1.14
52-Week Range
Now: $1.10
Volume108,012 shs
Average Volume596,373 shs
Market Capitalization$26.16 million
P/E RatioN/A
Dividend YieldN/A
Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.
Read More
Neurotrope logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.59 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:NTRP



Sales & Book Value

Annual SalesN/A
Book Value$1.33 per share


Net Income$-15,140,000.00


Market Cap$26.16 million
Next Earnings Date11/10/2020 (Estimated)
-0.01 (-0.90 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NTRP News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Neurotrope (NASDAQ:NTRP) Frequently Asked Questions

How has Neurotrope's stock been impacted by Coronavirus?

Neurotrope's stock was trading at $0.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NTRP shares have increased by 26.4% and is now trading at $1.10.
View which stocks have been most impacted by COVID-19

When is Neurotrope's next earnings date?

Neurotrope is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Neurotrope

How were Neurotrope's earnings last quarter?

Neurotrope Inc (NASDAQ:NTRP) released its earnings results on Monday, August, 10th. The company reported ($0.13) earnings per share (EPS) for the quarter.
View Neurotrope's earnings history

Are investors shorting Neurotrope?

Neurotrope saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 156,500 shares, an increase of 66.7% from the August 31st total of 93,900 shares. Based on an average daily volume of 204,700 shares, the days-to-cover ratio is presently 0.8 days.
View Neurotrope's Short Interest

Who are some of Neurotrope's key competitors?

What other stocks do shareholders of Neurotrope own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurotrope investors own include Sarepta Therapeutics (SRPT), Neos Therapeutics (NEOS), Fibrocell Science (FCSC), Alibaba Group (BABA), KemPharm (KMPH), Pieris Pharmaceuticals (PIRS), Sorrento Therapeutics (SRNE), Canopy Growth (CGC), Intel (INTC) and OrganiGram (OGI).

Who are Neurotrope's key executives?

Neurotrope's management team includes the following people:
  • Dr. Charles S. Ryan, CEO & Director (Age 55)
  • Dr. Daniel L. Alkon, Pres & Chief Scientific Officer (Age 77)
  • Mr. Robert Weinstein, CFO, Exec. VP, Sec. & Treasurer (Age 59)
  • Dr. Michael Ciraolo, Gen. Counsel & COO (Age 46)
  • Mr. Jeffrey Benison, Director of Corp. Communications

What is Neurotrope's stock symbol?

Neurotrope trades on the NASDAQ under the ticker symbol "NTRP."

Who are Neurotrope's major shareholders?

Neurotrope's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Two Sigma Advisers LP (0.21%).
View institutional ownership trends for Neurotrope

Which major investors are buying Neurotrope stock?

NTRP stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP.
View insider buying and selling activity for Neurotrope

How do I buy shares of Neurotrope?

Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Neurotrope's stock price today?

One share of NTRP stock can currently be purchased for approximately $1.10.

How big of a company is Neurotrope?

Neurotrope has a market capitalization of $26.16 million. Neurotrope employs 6 workers across the globe.

What is Neurotrope's official website?

The official website for Neurotrope is www.neurotropebioscience.com.

How can I contact Neurotrope?

Neurotrope's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973-242-0005 or via email at [email protected]

This page was last updated on 9/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.